An Antimicrobial susceptibility study to compare the in vitro activity of antimicrobial agents in the Philippines against Enterobacterales and Pseudomonas aeruginosa from different infection sites: results from ATLAS surveillance program (2018-2021)
Abstract
Background: This antimicrobial surveillance study reports the in vitro antimicrobial activity and susceptibility data of various antimicrobials against Enterobacterales and Pseudomonas aeruginosa isolates in the Philippines.
Methods: Isolates were collected from three clinical sites in the Philippines between 2018 and 2021, as part of the Antimicrobial Testing Leadership and Surveillance (ATLAS) program. A central laboratory (International Health Management Associates, Inc.) performed antimicrobial susceptibility testing using broth microdilution methodology according to Clinical Laboratory Standards Institute (CLSI) guidelines. Minimum inhibitory concentrations (MICs) were interpreted using the CLSI (2023) breakpoints.
Results: A total of 1503 isolates were collected in the ATLAS program from 2018 to 2021. The top three pathogens throughout the study period were Pseudomonas aeruginosa (30.8%), Klebsiella pneumoniae (24.1%), and Escherichia coli (20.8%). Based on the CLSI (2023) breakpoints, isolates of Enterobacterales were highly susceptible to amikacin (98.6%), tigecycline (96.9%) and ceftazidime-avibactam (95.9%), while P. aeruginosa isolates were most susceptible to amikacin (96.5%), ceftazidime-avibactam (94.0%) and ceftolozane-tazobactam (92.7%).
Conclusion: The present ATLAS study provides essential insights on the prevalence and susceptibility patterns of Enterobacterales and P. aeruginosa isolates in the Philippines. Ceftazidime-avibactam is a valuable and…
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.